AstraZeneca (OMXS: AZN) reaffirmed short and medium-term forecasts this morning after an inadvertant leak of an out-of-date spreadsheet templeta to sell-side analyst community in connection with a routine consensus estimate collection process had raised some questions. AstraZeneca maintains 2011 expextations communicated on December 20th.
The company also reaffirms assumptions for revenue, margins and cash deployment for 2010-2014 last updated a year ago in connection with the Q4 2010 interim report. These include a revenue target of $28bn to $34bn per annum, lowered current pipeline contribution into revenue forecasted to be in place by 2014, double-digit growth in emerging markets, a gross margin target above 80%, progressive dividend and periodic share repurchases and 40-50% of after-tax cash flow reinvested into R&D.
No comments:
Post a Comment